Clinical trials: HIV Reservoir
HIV Infection, Cancer
Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer
It has been reported that peripheral and lymph node resident Cluster of Differentiation 4 (CD4)+ T cells expressing Programmed cell death protein 1 (PD-1) contribute to Human Immunodeficiency Virus (HIV) persistence during…
- Trial name
- PembroHIV (NCT03767465)
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- IrsiCaixa
HIV/AIDS
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir
A longitudinal observational study in HIV-infected subjects receiving cART addressed to explore the effect of the Tat protein and anti-Tat immunity on the formation and maintenance of HIV-1 virus reservoir.
- Trial name
- ISS OBS T-005 (NCT04263207)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Barbara Ensoli, MD, PhD
Human Immunodeficiency Virus (HIV)
Romidepsin Plus 3BNC117 Phase 2a Study
The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
- Trial name
- ROADMAP (NCT02850016)
- Testing
- 3BNC117, Romidepsin
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 48 people
- Sponsor
- Rockefeller University
HIV Infections
Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV
Sixty HIV participants will be enrolled and stratified by PBMC HIV DNA levels, either high (greater than or equal to 5000 copies/106 cells) or low (less than 5000 copies/106 cells).
- Trial name
- NCT00782808
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- SEARCH Research Foundation
HIV Positive
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
The health of the immune system in HIV infected people is currently determined from a blood test measuring the number of cluster of differentiation 4 (CD4) T lymphocytes. These cells play a critical role in an immune response.
- Trial name
- QFM (NCT01904201)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- QIAGEN Gaithersburg, Inc
HIV-1-infection
A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption.
- Trial name
- NCT04985890
- Testing
- UB-421, UB-421+chidamide
- Volunteers
- 20 people
- Sponsor
- UBP Greater China (Shanghai) Co., Ltd
HIV-1-infection
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir.
- Trial name
- AMBER (NCT05668026)
- Testing
- Venetoclax
- Where
- 2 sites in Australia, Denmark
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
HIV Infections
A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a
To analyze the HIV viral sequences present in the CD32 + CD4a + T lymphocytes of the patients who have participated in the ANRS 139 TRIO trial, always followed and in virological success, and carrying multi-resistant viruses…
- Trial name
- ANRS EP63 (NCT03298360)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 11 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
The purpose of this study is to determine whether a two-week course of disulfiram will reduce the HIV-1 latent reservoir in patients on highly active antiretroviral therapy (HAART).
- Trial name
- NCT01286259
- Testing
- Disulfiram
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection.
- Trial name
- NCT05419024
- Testing
- Acute Treatment Interruption
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen
The purpose of this study is to assess changes in viral reservoir after changing IP/r to dolutegravir in HIV-1 infected patients maintaining undetectable viral load on Antiretroviral Therapy (ART).
- Trial name
- NCT02513147
- Testing
- Dolutegravir, PI, 2 NRTI
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
HIV Infections
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load < 50…
- Trial name
- PLUS (NCT00884793)
- Testing
- raltegravir, Study NNRTI, Study PI
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
HIV Infection
Impact of Raltegravir on the Viral Reservoirs
The objective of the antiretroviral treatment is to inhibit the viral replication, estimated(appreciated) by the measure of the viral plasmatic load(responsibility).
- Trial name
- NCT01249560
- Sponsor
- Centre Hospitalier Universitaire de Nice
HIV Infections
Immunomodulators on HIV-1 Reservoir
The goal of this clinical trial is to learn about the function of immunomodulators in reducing HIV reservoir. The main questions it aims to answer are: Are immunomodulators able to reduce HIV reservoirs? How do immunomodulators…
- Trial name
- NCT05598580
- Testing
- Lenalidomide, Adenosylmethionine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
HIV Infection
Triple vs. Double Therapy in naïves HIV-Infected Patients
The objective of this study is to clarify whether if starting antiretroviral treatment based on dual therapy (DTG + 3TC) could provide less control of residual HIV replication and, therefore, a detriment on immune activation and…
- Trial name
- TRIDUNA (NCT04295460)
- Testing
- Randomize
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV-1-infection, Hiv
Studying Topiramate for Re-Activating the HIV-1 Reservoir
Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible…
- Conditions
- HIV-1-infection, Hiv, HIV Infections, HIV I Infection
- Trial name
- STAR (NCT06282783)
- Testing
- Topiramate
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
HIV Associated HCV
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
Spontaneous recovery of patients infected with HCV is related to the development of a cytotoxic immune response that is executed by specialized white blood cells, the CD8+ T cells, which develop a virus-specific response.
- Trial name
- HCURE (NCT03244371)
- Testing
- blood draw
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Lymphoma, Nonneoplastic Condition
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
- Trial name
- NCT01319526
- Testing
- DNA analysis, RNA analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- AIDS Malignancy Consortium
HIV-1-infection
BCG Vaccination Effect on Latent Reservoir Size in Treated HIV-1 Infection:
A phase IIA randomized double-blind placebo-controlled single-centre study of the effect of Bacillus Calmette-Guérin (BCG) vaccination on the HIV latent reservoir
- Trial name
- BELIEVE (NCT05004038)
- Testing
- BCG Vaccine AJVaccines
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Zurich
HIV-1 Infection
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
- Trial name
- NCT03743376
- Testing
- UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W
- Where
- 3 sites in Taiwan
- Volunteers
- 31 people
- Sponsor
- United BioPharma